đź“Ť Mobile Treatment Unit's current location:

Exploring the Concept of Treatment Refractory Addiction

Schedule An Appointment

MATClinics Explores the Concept of Treatment Refractory Addiction

By Dan Reck, CEO, MATClinics News
August 2025

‍

A New Paradigm in Understanding Addiction Treatment

For many battling substance use disorders (SUDs), treatment can feel like an uphill battle. MATClinics is stepping up to redefine how we understand and address these challenges by exploring the concept of Treatment Refractory Addiction (TRA) through the lens of psychiatric insights. 

Pioneering Research for Enhanced Care

Our latest publication, "The Concept of Treatment Refractory Addiction: Drawing on Psychiatric Insights to Improve Addiction Research," delves into the complexities of TRA, a term that encapsulates the difficulty some patients have in responding to standard treatments. Authored by Albert Burgess-Hull, PhD, this work proposes that frameworks from psychiatric conditions like depression and schizophrenia can inform better strategies for SUDs.

Key Insights

What We Explored:

  • Variability in Treatment Response: Understanding that not all patients respond equally to treatments is crucial. Around 34-39% of patients continue high substance use despite treatment—a clear call for tailored approaches.
  • Suboptimal Treatment Exposure: It's essential to differentiate between true refractoriness and cases of inadequate treatment exposure due to issues like poor adherence or incorrect dosing.
  • Primary vs. Secondary Refractoriness: Identifying whether nonresponse is immediate (primary) or develops over time (secondary) can lead to more targeted interventions.

Leveraging Psychiatric Frameworks

By borrowing concepts from psychiatric disorders, we can better define and understand TRA. This includes distinguishing between suboptimal treatment exposure and true refractoriness, and utilizing advanced analytics like unsupervised clustering to identify patient subgroups.

Why This Matters

Exploring TRA is more than academic—it’s about improving patient outcomes and personalizing care. Here’s how we’re making strides:

  • Individualized Interventions: We are committed to tailoring treatment plans to meet the specific needs of each patient. By identifying and flagging likely non-responders early—those whose treatment trajectories resemble Treatment Refractory Addiction (TRA) phenotypes documented across multiple Substance Use Disorder (SUD) studies—we can promptly adjust care pathways. This proactive approach aims to improve outcomes for a population that has historically been underserved. 
  • Advanced Research Methods: We employ machine learning techniques to deepen our understanding and develop innovative treatment strategies. These advanced methods allow us to identify patterns and predict treatment outcomes more accurately, paving the way for more effective interventions. 
  • Holistic Care Approaches: Our approach addresses all factors contributing to treatment outcomes, from biological to environmental aspects. By considering the full spectrum of influences on a patient’s health, we strive to offer comprehensive care that supports recovery on all levels. 

Integrating Research Into Our Mission

At MATClinics, research and clinical practice go hand in hand. By continuously refining our understanding of TRA, we ensure our treatments are as effective and personalized as possible, offering patients the best chance at recovery.